Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer - Episode 16

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

, , , , ,

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

EP. 1: Overview of Current mCRC Treatment Landscape
EP. 2: Evaluating 3L Treatment Landscape Evolution
EP. 3: Fruquintinib MoA and Toxicity Profile Overview
EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
EP. 5: FRESCO-2 Study Highlights
EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
EP. 8: Consideration for Fruquintinib Dosing and Titration
EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
EP. 11: Considerations for Platinum-based Therapy
EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024
EP. 15: Unmet Needs Surrounding mCRC Treatment
Now Viewing
EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Related Content:

Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal CancerCity of HopeMoffitt Cancer CenterBaylor Scott & White Charles A. Sammons Cancer Center Allina Health SystemColorectal CancerOncLive Peer Exchange®
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease
Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients
Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC